<VariationArchive VariationID="15414" VariationName="NM_000518.5(HBB):c.51del (p.Lys18fs)" VariationType="Deletion" Accession="VCV000015414" Version="115" RecordType="classified" NumberOfSubmissions="18" NumberOfSubmitters="18" DateLastUpdated="2024-07-29" DateCreated="2015-06-28" MostRecentSubmission="2024-06-02">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30453" VariationID="15414">
      <GeneList>
        <Gene Symbol="HBB" FullName="hemoglobin subunit beta" GeneID="3043" HGNC_ID="HGNC:4827" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5225464" stop="5227071" display_start="5225464" display_stop="5227071" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5246695" stop="5248300" display_start="5246695" display_stop="5248300" Strand="-" />
          </Location>
          <OMIM>141900</OMIM>
        </Gene>
        <Gene Symbol="LOC106099062" FullName="HBB recombination region" GeneID="106099062" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5226570" stop="5228834" display_start="5226570" display_stop="5228834" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC107133510" FullName="origin of replication at HBB" GeneID="107133510" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5222166" stop="5229620" display_start="5222166" display_stop="5229620" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000518.5(HBB):c.51del (p.Lys18fs)</Name>
      <CanonicalSPDI>NC_000011.10:5226970:G:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11p15.4</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5226971" stop="5226971" display_start="5226971" display_stop="5226971" variantLength="1" positionVCF="5226970" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5248201" stop="5248201" display_start="5248201" display_stop="5248201" variantLength="1" positionVCF="5248200" referenceAlleleVCF="TG" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>CD 16 GGC&gt;GG-</Name>
      </OtherNameList>
      <ProteinChange>K18fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.5226971del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.5226971del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.5248201del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.5248201del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000007.3" sequenceAccession="NG_000007" sequenceVersion="3" change="g.70645del">
            <Expression>NG_000007.3:g.70645del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042296.1" sequenceAccession="NG_042296" sequenceVersion="1" change="g.502del">
            <Expression>NG_042296.1:g.502del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046672.1" sequenceAccession="NG_046672" sequenceVersion="1" change="g.4906del">
            <Expression>NG_046672.1:g.4906del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059281.1" sequenceAccession="NG_059281" sequenceVersion="1" change="g.5101del">
            <Expression>NG_059281.1:g.5101del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.5" sequenceAccession="NM_000518" sequenceVersion="5" change="c.51del" MANESelect="true">
            <Expression>NM_000518.5:c.51del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000509.1" sequenceAccession="NP_000509" sequenceVersion="1" change="p.Lys18fs">
            <Expression>NP_000509.1:p.Lys18fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232" sequenceAccession="LRG_1232">
            <Expression>LRG_1232:g.5101del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232t1" sequenceAccession="LRG_1232t1">
            <Expression>LRG_1232t1:c.51del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1232p1" sequenceAccession="LRG_1232p1" change="p.Lys18fs">
            <Expression>LRG_1232p1:p.Lys18fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.4" sequenceAccession="NM_000518" sequenceVersion="4" change="c.51del">
            <Expression>NM_000518.4:c.51del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.5" sequenceAccession="NM_000518" sequenceVersion="5" change="c.51delC" MANESelect="true">
            <Expression>NM_000518.5:c.51delC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="799" DB="HBVAR" />
        <XRef ID="CA125280" DB="ClinGen" />
        <XRef ID="GTR000500319" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
        <XRef Type="Allelic variant" ID="141900.0323" DB="OMIM" />
        <XRef Type="rs" ID="35662066" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00003" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00003" Source="The Genome Aggregation Database (gnomAD), exomes" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND Beta zero thalassemia" Accession="RCV000016670" Version="36">
        <ClassifiedConditionList TraitSetID="4683">
          <ClassifiedCondition DB="MedGen" ID="C0271980">Beta zero thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2017-02-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND beta Thalassemia" Accession="RCV000173145" Version="19">
        <ClassifiedConditionList TraitSetID="4697">
          <ClassifiedCondition DB="MedGen" ID="C0005283">beta Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2019-12-17" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND Hemoglobinopathy" Accession="RCV000590756" Version="9">
        <ClassifiedConditionList TraitSetID="11981">
          <ClassifiedCondition DB="MedGen" ID="C0019045">Hemoglobinopathy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-10-31" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND not provided" Accession="RCV000724162" Version="31">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-01-04" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND multiple conditions" Accession="RCV002482874" Version="8">
        <ClassifiedConditionList TraitSetID="82018">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1858990">Dominant beta-thalassemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4693822">Erythrocytosis, familial, 6</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002895">Hb SS disease</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0700299">Heinz body anemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0019025">Hereditary persistence of fetal hemoglobin</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1840779">METHEMOGLOBINEMIA, BETA TYPE</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1970028">Malaria, susceptibility to</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND Inborn genetic diseases" Accession="RCV002336087" Version="9">
        <ClassifiedConditionList TraitSetID="25797">
          <ClassifiedCondition DB="MedGen" ID="C0950123">Inborn genetic diseases</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2017-05-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND Beta-thalassemia HBB/LCRB" Accession="RCV003227603" Version="10">
        <ClassifiedConditionList TraitSetID="80504">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.51del (p.Lys18fs) AND HBB-related disorder" Accession="RCV004532367" Version="1">
        <ClassifiedConditionList TraitSetID="33481">
          <ClassifiedCondition DB="MedGen" ID="CN239378">HBB-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-06-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-01-04" NumberOfSubmissions="18" NumberOfSubmitters="18" DateCreated="2015-06-28" MostRecentSubmission="2024-06-02">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <CitationText>Kazazian, H. H., Jr. Personal Communication. 1982. Baltimore, Md.</CitationText>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">11791873</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12368169</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12403498</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12779277</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18294253</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18954999</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19254853</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2064964</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21389146</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22239493</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22392582</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23637309</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25135424</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25412720</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26076395</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26594346</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27263053</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27828729</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29295702</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30046479</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30489691</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31190580</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32412692</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33602051</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33829933</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">6714226</ID>
        </Citation>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=HBB</URL>
        </Citation>
        <Citation Type="general">
          <URL>https://ithanet.eu/db/ithagenes?ithaID=75</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="4683" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="11956" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta zero thalassemia</ElementValue>
                <XRef ID="86715000" DB="SNOMED CT" />
              </Name>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-EE-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FE, Hemoglobin EE or Hemoglobin E/Beta Zero Thalassemia (Hb EE or Hb E/ß0 Disease), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0271980" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33481" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36575" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HBB-Related Disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HBB-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">HBB-related disorder</ElementValue>
              </Name>
              <XRef ID="CN239378" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4697" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="11970" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cooley's anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Erythroblastic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mediterranean anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
                <XRef ID="Beta+Thalassemia/814" DB="Genetic Alliance" />
                <XRef ID="65959000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="871" />
                <XRef ID="871" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000515560" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520044" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592332" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000567333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520115" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596318" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260581" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529085" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592286" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508856" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521590" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558937" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501386" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592287" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-E-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FEA, Hemoglobin E/Beta Plus Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C0005283" DB="MedGen" />
              <XRef ID="MONDO:0019402" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="11981" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16728" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Haemoglobinopathies</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hemoglobinopathy</ElementValue>
                <XRef ID="MONDO:0044348" DB="MONDO" />
                <XRef ID="80141007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin disorder</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12455" />
                <XRef ID="12455" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <XRef ID="C0019045" DB="MedGen" />
              <XRef ID="MONDO:0044348" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="82018" Type="TraitChoice" ContributesToAggregateClassification="true">
            <Trait ID="40028" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Erythrocytosis, familial, 6</ElementValue>
                <XRef ID="MONDO:0054801" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ECYT6</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Symbol>
              <XRef ID="C4693822" DB="MedGen" />
              <XRef ID="MONDO:0054801" DB="MONDO" />
              <XRef Type="MIM" ID="617980" DB="OMIM" />
            </Trait>
            <Trait ID="16291" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">METHEMOGLOBINEMIA, BETA TYPE</ElementValue>
                <XRef Type="MIM" ID="617971" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0163" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0164" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methemoglobinemia, beta-globin type</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13007" />
                <XRef ID="13007" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C1840779" DB="MedGen" />
              <XRef Type="MIM" ID="617971" DB="OMIM" />
            </Trait>
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
            <Trait ID="5915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sickle cell anemia</ElementValue>
                <XRef ID="MONDO:0011382" DB="MONDO" />
                <XRef ID="232" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hb SS disease</ElementValue>
                <XRef ID="127040003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickle cell disease</ElementValue>
                <XRef ID="C34383" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HbS disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin S Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickling disorder due to hemoglobin S</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8614" />
                <XRef ID="8614" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.</Attribute>
                <XRef ID="NBK1377" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301551</ID>
                <ID Source="BookShelf">NBK1377</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2009">
                <ID Source="PubMed">19323364</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3111605</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="Yawn et al., 2014">
                <ID Source="PubMed">25203083</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-NBS-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet, [FAS] Sickle Cell Carrier (HbAS)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-S-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb S Screening, 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Carrier Screening ACT Sheet, Sickle Cell Carrier/Trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Disease-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Sickle Cell Disease, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-AS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FAS: Sickle Cell Trait Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="232" DB="Orphanet" />
              <XRef ID="C0002895" DB="MedGen" />
              <XRef ID="MONDO:0011382" DB="MONDO" />
              <XRef Type="MIM" ID="603903" DB="OMIM" />
            </Trait>
            <Trait ID="5228" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Heinz body anemias</ElementValue>
                <XRef ID="Heinz+body+anemias/3265" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Heinz body hemolytic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Heinz body anemia</ElementValue>
                <XRef ID="HP:0005511" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007705" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10718" />
                <XRef ID="10718" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="178330" DB="Orphanet" />
              <XRef ID="C0700299" DB="MedGen" />
              <XRef ID="MONDO:0007705" DB="MONDO" />
              <XRef Type="MIM" ID="140700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0005511" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="55601" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary persistence of fetal hemoglobin</ElementValue>
                <XRef ID="319672" DB="GeneTests" />
                <XRef ID="MONDO:0020989" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HPFH</ElementValue>
                <XRef Type="MIM" ID="141749" DB="OMIM" />
              </Symbol>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0019025" DB="MedGen" />
              <XRef ID="MONDO:0020989" DB="MONDO" />
              <XRef Type="MIM" ID="141749" DB="OMIM" />
            </Trait>
            <Trait ID="10300" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Malaria, susceptibility to</ElementValue>
                <XRef ID="MONDO:0021024" DB="MONDO" />
              </Name>
              <XRef ID="673" DB="Orphanet" />
              <XRef ID="C1970028" DB="MedGen" />
              <XRef ID="MONDO:0021024" DB="MONDO" />
              <XRef Type="MIM" ID="611162" DB="OMIM" />
            </Trait>
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
            <Trait ID="383" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">DYSERYTHROPOIETIC ANEMIA, CONGENITAL, IRISH OR WEATHERALL TYPE</ElementValue>
                <XRef Type="MIM" ID="603902" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-thalassemia, dominant inclusion body type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Dominant beta-thalassemia</ElementValue>
                <XRef ID="MONDO:0011381" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">D-BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17164" />
                <XRef ID="17164" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="231226" DB="Orphanet" />
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C1858990" DB="MedGen" />
              <XRef ID="MONDO:0011381" DB="MONDO" />
              <XRef Type="MIM" ID="603902" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25797" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="32761" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Inborn genetic diseases</ElementValue>
              </Name>
              <Citation Type="general" Abbrev="Langer et al., 2012">
                <ID Source="PubMed">22947299</ID>
              </Citation>
              <Citation Type="general" Abbrev="SACHDNC, 2013">
                <ID Source="PubMed">23037933</ID>
              </Citation>
              <Citation Type="general" Abbrev="EASAC/FEAM, 2013">
                <ID Source="PubMed">23169492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESHG/P3G/HUGO/PHGF, 2015">
                <ID Source="PubMed">25626707</ID>
              </Citation>
              <Citation Type="general" Abbrev="Alpha-1 Foundation, 2014">
                <ID Source="PubMed">24121147</ID>
              </Citation>
              <Citation Type="general" Abbrev="NBSTRN, 2015">
                <ID Source="PubMed">24394680</ID>
              </Citation>
              <Citation Type="general" Abbrev="EUNENBS, 2014">
                <ID Source="PubMed">23652378</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2014">
                <ID Source="PubMed">23881473</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/ACOG/NSGC/PQF/SMFM, 2015">
                <ID Source="PubMed">25730230</ID>
              </Citation>
              <Citation Type="general" Abbrev="Skirton et al., 2014">
                <ID Source="PubMed">24022298</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23619275</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2019">
                <ID Source="PubMed">31022120</ID>
              </Citation>
              <XRef ID="C0950123" DB="MedGen" />
              <XRef ID="D030342" DB="MeSH" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="80504" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="36940" SubmissionDate="2017-02-27" DateLastUpdated="2017-03-02" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="141900.0323_BETA-ZERO-THALASSEMIA" title="HBB, GLY16FS_BETA-ZERO-THALASSEMIA" />
        <ClinVarAccession Accession="SCV000036940" DateUpdated="2017-03-02" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-02-27">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">A frameshift mutation, -C, codon 16, GGC to GG, in the HBB gene was found in Asian Indians with beta-zero-thalassemia (613985) by Kazazian et al. (1984).</Attribute>
              <Citation>
                <CitationText>Kazazian, H. H., Jr. Personal Communication. 1982. Baltimore, Md.</CitationText>
              </Citation>
              <XRef DB="OMIM" ID="613985" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <Name>HBB, GLY16FS</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">GLY16FS</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="141900.0323" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BETA-ZERO-THALASSEMIA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1363489" SubmissionDate="2018-01-25" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_000518.4:c.51delC|MedGen:C0019045" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000697137" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-10-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18294253</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19254853</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12368169</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22239493</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22392582</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12779277</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12403498</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18954999</ID>
          </Citation>
          <Comment>Variant summary: The HBB c.51delC (p.Lys18Argfs) variant results in a premature termination codon, predicted to cause a truncated or absent HBB protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.85dupC, c.135delC). Mutation taster predicts a damaging outcome for this variant. This variant was found in 4/121395 control chromosomes at a frequency of 0.000033, which does not exceed the estimated maximal expected allele frequency of a pathogenic HBB variant (0.0111803). It was reported in several BTHAL patients some of whom were homologous for the variant indicating causality. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="35662066" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0019045" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="412538" SubmissionDate="2018-09-19" DateLastUpdated="2018-12-15" DateCreated="2015-06-28">
        <ClinVarSubmissionID localKey="21984_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000224234" DateUpdated="2018-12-15" DateCreated="2015-06-28" Type="SCV" Version="5" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-02-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL Classification Definitions 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/ahdynye1/egl_classification_definitions_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="-" referenceAllele="G" start="5248201" stop="5248201" variantLength="1" />
            <GeneLocation>NM_000518.4:Ex1</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="HGMD" ID="CD951723" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=HBB</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4534263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2454133" SubmissionDate="2019-11-25" DateLastUpdated="2020-04-24" DateCreated="2020-04-24">
        <ClinVarSubmissionID localKey="ithaID:75|Orphanet:ORPHA:848" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001244647" DateUpdated="2020-04-24" DateCreated="2020-04-24" Type="SCV" Version="1" SubmitterName="The ITHANET community portal, The Cyprus Institute of Neurology and Genetics" OrgID="507248" OrganizationCategory="locus-specific database (LSDB)" OrgAbbreviation="ITHANET" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27263053</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>CD 16 GGC&gt;GG-</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="35662066" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
            </Name>
            <XRef DB="Orphanet" ID="ORPHA848" />
          </Trait>
        </TraitSet>
        <Citation>
          <URL>https://ithanet.eu/db/ithagenes?ithaID=75</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB6599191</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2354621" SubmissionDate="2020-06-18" DateLastUpdated="2020-07-03" DateCreated="2020-04-06">
        <ClinVarSubmissionID localKey="58|OMIM:613985" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194166" DateUpdated="2020-07-03" DateCreated="2020-04-06" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000677928" DateChanged="2020-07-02" Version="2">
            <Comment Type="MergeComment">SCV000677928 was merged into SCV001194166 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2019-12-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">18294253</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21389146</ID>
          </Citation>
          <Comment>NM_000518.4(HBB):c.51delC(K18Rfs*2) is classified as pathogenic in the context of Hb beta chain-related hemoglobinopathy and is associated with beta thalassemia. Sources cited for classification include the following: PMID 18294253, 6714226 and 21389146. Classification of NM_000518.4(HBB):c.51delC(K18Rfs*2) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Women's Health Autosomal Recessive and X-Linked Classification Criteria (2019)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/vlxza0ea/myriad_women_s_health_autosomal_recessive_and_x-linked_classification_criteria_2019_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="T" referenceAllele="TG" start="5248200" stop="5248201" variantLength="2" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6849778</SubmissionName>
          <SubmissionName>SUB7605676</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2808781" SubmissionDate="2020-07-14" DateLastUpdated="2020-07-25" DateCreated="2020-07-25">
        <ClinVarSubmissionID localKey="NM_000518.4:c.51del|Beta-thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001424434" DateUpdated="2020-07-25" DateCreated="2020-07-25" Type="SCV" Version="1" SubmitterName="Centogene AG  - the Rare Disease Company" OrgID="279559" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Beta-thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>20200714_NPJ</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3094269" SubmissionDate="2021-04-15" DateLastUpdated="2021-04-24" DateCreated="2021-04-24">
        <ClinVarSubmissionID localKey="NM_000518.4:c.51delC|Beta thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001571584" DateUpdated="2021-04-24" DateCreated="2021-04-24" Type="SCV" Version="1" SubmitterName="Molecular Genetics Laboratory, BC Children's and BC Women's Hospitals" OrgID="249401" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-05">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Beta thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9478044</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4082850" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000518.5:c.51del|Beta thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002091600" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Beta thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5445736" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000518.5:c.51del|OMIM:140700;141749;603902;603903;604131;611162;613985;617971;617980" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002794108" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="140700" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="141749" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603902" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603903" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="611162" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617971" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617980" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7575351" SubmissionDate="2023-10-19" DateLastUpdated="2023-10-28" DateCreated="2023-10-28">
        <ClinVarSubmissionID localKey="20200108410" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004046932" DateUpdated="2023-10-28" DateCreated="2023-10-28" Type="SCV" Version="1" SubmitterName="Neuberg Centre For Genomic Medicine, NCGM" OrgID="508108" OrganizationCategory="laboratory" OrgAbbreviation="NCGM" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The frameshift variant has been reported previously in homozygous and compound heterozygous state in patients affected with beta-thalassemia (Krugluger W. et al., 2002; Yasmeen H. et al., 2016). The p.Lys18ArgfsTer2 variant is reported with the allele frequency (0.003%) in the gnomad and novel in 1000 genome database. It has been submitted to ClinVar as a Pathogenic variant. This variant causes a frameshift starting with codon Lysine 18, changes this amino acid to Arginine residue, and creates a premature Stop codon at position 2 of the new reading frame, denoted p.Lys18ArgfsTer2. The variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic. In the absence of another reportable variant , the molecular diagnosis of recessive thalassemia is not confirmed.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0004840" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001903" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001433" />
              </Trait>
              <Comment>Age: 1 year 5 months/ Male Clinical indication: Repeated transfusions, Hepatosplenomegaly, Thalassemia major ruled out. Clinical suspicion: Congenital hemolytic anemia</Comment>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13901154</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4013401" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2022-01-03">
        <ClinVarSubmissionID localKey="S8464|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002047330" DateUpdated="2024-01-06" DateCreated="2022-01-03" Type="SCV" Version="2" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">33829933</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">33602051</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31190580</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32412692</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30489691</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30046479</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29295702</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11791873</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2064964</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25412720</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22392582</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25135424</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27263053</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27828729</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26076395</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19254853</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18294253</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12368169</ID>
          </Citation>
          <Comment>The HBB c.51del (p.Lys18Argfs*2) variant (also known as Codon 16 (-C)) alters the translational reading frame of the HBB mRNA and causes the premature termination of HBB protein synthesis. This variant is associated with beta(0)-thalassemia (PMIDs: 33602051(2021), 30046479 (2018), 29295702 (2018), 27828729 (2017), 26076395 (2015), and 22392582 (2012)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10813355</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1732110" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2018-12-15">
        <ClinVarSubmissionID localKey="2291|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000885547" DateUpdated="2024-02-20" DateCreated="2018-12-15" Type="SCV" Version="4" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The Codon 16 (-C) variant (HBB: c.51delC; p.Lys18fs, also known as Lys17fs when numbered from the mature protein, rs35662066, HbVar ID: 799) is reported in the literature in individuals with beta-thalassemia trait (Kazazian 1984, Panja 2017, Varawalla 1991, Yasmeen 2016, HbVar and references therein). This variant is reported in ClinVar (Variation ID: 15414), and is only observed on eight alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Kazazian HH Jr et al. Molecular characterization of seven beta-thalassemia mutations in Asian Indians. EMBO J. 1984; 3(3):593-6. PMID: 6714226. Panja A et al. Cross-Sectional Study for the Detection of Mutations in the Beta-Globin Gene Among Patients with Hemoglobinopathies in the Bengali Population. Genet Test Mol Biomarkers. 2017; 21(1):39-45. PMID: 27828729. Varawalla N et al. The spectrum of beta-thalassaemia mutations on the Indian subcontinent: the basis for prenatal diagnosis. Br J Haematol. 1991; 78(2):242-7. PMID: 2064964. Yasmeen H et al. The molecular characterization of Beta globin gene in thalassemia patients reveals rare and a novel mutations in Pakistani population. Eur J Med Genet. 2016; 59(8):355-62. PMID: 27263053.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5248201del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5130000" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2022-11-29">
        <ClinVarSubmissionID localKey="a6348|MedGen:C0950123" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002644409" DateUpdated="2024-05-01" DateCreated="2022-11-29" Type="SCV" Version="2" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-05-26">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25135424</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26594346</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6714226</ID>
          </Citation>
          <Comment>The c.51delC (also known as Codon 16 del C) pathogenic mutation, located in coding exon 1 of the HBB gene, results from a deletion of one nucleotide at nucleotide position 51, causing a translational frameshift with a predicted alternate stop codon (p.K18Rfs*2). This mutation was identified in multiple Asian Indian individuals with beta thalassemia (Kazazian HH et al. EMBO J., 1984 Mar;3:593-6; Italia K et al. Br. J. Haematol., 2015 Jan;168:156-9; Rajab A et al. F1000Res, 2015 Sep;4:891). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0950123" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2862495" SubmissionDate="2020-11-26" DateLastUpdated="2020-12-10" DateCreated="2020-12-10">
        <ClinVarSubmissionID localKey="NM_000518.5:c.51del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001449629" DateUpdated="2020-12-10" DateCreated="2020-12-10" Type="SCV" Version="1" SubmitterName="Clinical Genetics and Genomics, Karolinska University Hospital" OrgID="505315" OrganizationCategory="laboratory" OrgAbbreviation="KLINGEN-KUS" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8639822</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7337579" SubmissionDate="2023-05-17" DateLastUpdated="2023-05-20" DateCreated="2023-05-20">
        <ClinVarSubmissionID localKey="SUB13362371" submittedAssembly="hg19" title="SUB13362371" />
        <ClinVarAccession Accession="SCV003925064" DateUpdated="2023-05-20" DateCreated="2023-05-20" Type="SCV" Version="1" SubmitterName="Lifecell International Pvt. Ltd" OrgID="507720" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">21389146</ID>
          </Citation>
          <Comment>A Heterozygous Frameshift variant c.51delC in Exon 1 of the HBB gene that results in the amino acid substitution p.Lys18fs*2 was identified. The observed variant has a minor allele frequency of 0.00003% in gnomAD exomes and genomes, respectively. The severity of the impact of this variant on the protein is high, based on the effect of the protein and REVEL score. Rare Exome Variant Ensemble Learner (REVEL) is an ensembl method for predicting the pathogenicity of missense variants based on a combination of scores from 13 individual tools: MutPred, FATHMM v2.3, VEST 3.0, PolyPhen-2, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP++, SiPhy, phyloP, and phastCons. The REVEL score for an individual missense variant can range from 0 to 1, with higher scores reflecting greater likelihood that the variant is disease-causing. ClinVar has also classified this variant as Pathogenic (Variation ID: 15414).The variant has been previously reported by Neu-Yilik G, et al., 2011. Based on the above evidence this variant has been classified as Pathogenic according to the ACMG guidelines.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Asian</Ethnicity>
              <GeographicOrigin>India</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <NamePlatform>NovaSeq 6000</NamePlatform>
              <TypePlatform>Next-generation exome sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB">
              <Name>hemoglobin subunit beta</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000518.5:exon 1</GeneLocation>
          </Location>
          <XRefList>
            <XRef DB="dbSNP" ID="rs35662066" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13362371</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7696673" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="3569481|HBB-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004116754" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBB c.51delC variant is predicted to result in a frameshift and premature protein termination (p.Lys18Argfs*2). This variant, also referred to as Codon 16(-C), has been reported to be causative for beta thalassaemia (Edison et al. 2008. PubMed ID: 18294253; Kazazian et al. 1984. PubMed ID: 6714226). This variant is reported in 0.026% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/11-5248200-TG-T). Frameshift variants in HBB are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HBB-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2375893" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4890580|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001210575" DateUpdated="2024-02-14" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23637309</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12368169</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12403498</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27263053</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Lys18Argfs*2) in the HBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). This variant is present in population databases (rs35662066, gnomAD 0.03%). This premature translational stop signal has been observed in individual(s) with autosomal recessive beta-thalassemia (PMID: 12368169, 12403498, 27263053). It has also been observed to segregate with disease in related individuals. This variant is also known as "Codon 16 (-C)". ClinVar contains an entry for this variant (Variation ID: 15414). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5248201del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9796146" SubmissionDate="2024-05-30" DateLastUpdated="2024-06-02" DateCreated="2024-06-02">
        <ClinVarSubmissionID localKey="1695572|Not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005046492" DateUpdated="2024-06-02" DateCreated="2024-06-02" Type="SCV" Version="1" SubmitterName="Mayo Clinic Laboratories, Mayo Clinic" OrgID="500068" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-01-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000518.4:exon 1</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.51delC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14491975</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="617971" MappingRef="OMIM">
        <MedGen CUI="C1840779" Name="METHEMOGLOBINEMIA, BETA TYPE" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="603903" MappingRef="OMIM">
        <MedGen CUI="C0002895" Name="Hb SS disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4013401" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575351" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001433" MappingRef="HP">
        <MedGen CUI="C0019214" Name="Hepatosplenomegaly" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2454133" TraitType="Disease" MappingType="Name" MappingValue="beta Thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2862495" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="140700" MappingRef="OMIM">
        <MedGen CUI="C0700299" Name="Heinz body anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3094269" TraitType="Disease" MappingType="Name" MappingValue="Beta thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="603902" MappingRef="OMIM">
        <MedGen CUI="C1858990" Name="Dominant beta-thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="412538" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4082850" TraitType="Disease" MappingType="Name" MappingValue="Beta thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575351" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2375893" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2808781" TraitType="Disease" MappingType="Name" MappingValue="Beta-thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="141749" MappingRef="OMIM">
        <MedGen CUI="C0019025" Name="Hereditary persistence of fetal hemoglobin" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1363489" TraitType="Disease" MappingType="XRef" MappingValue="C0019045" MappingRef="MedGen">
        <MedGen CUI="C0019045" Name="Hemoglobinopathy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="611162" MappingRef="OMIM">
        <MedGen CUI="C1970028" Name="Malaria, susceptibility to" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9796146" TraitType="Disease" MappingType="Name" MappingValue="Not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5130000" TraitType="Disease" MappingType="XRef" MappingValue="C0950123" MappingRef="MedGen">
        <MedGen CUI="C0950123" Name="Inborn genetic diseases" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="617980" MappingRef="OMIM">
        <MedGen CUI="C4693822" Name="Erythrocytosis, familial, 6" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2354621" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7696673" TraitType="Disease" MappingType="Name" MappingValue="HBB-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239378" Name="HBB-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5445736" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="36940" TraitType="Disease" MappingType="Name" MappingValue="BETA-ZERO-THALASSEMIA" MappingRef="Preferred">
        <MedGen CUI="C0271980" Name="Beta zero thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575351" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001903" MappingRef="HP">
        <MedGen CUI="C0002871" Name="Anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7337579" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7575351" TraitType="Finding" MappingType="XRef" MappingValue="HP:0004840" MappingRef="HP">
        <MedGen CUI="C0271901" Name="Hypochromic microcytic anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1732110" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

